Results 141 to 150 of about 261,105 (346)

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

New England Journal of Medicine, 2006
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David H. Johnson   +7 more
semanticscholar   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

Advanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang   +8 more
wiley   +1 more source

Tumor‐Targeted FABP5/STING Cascade Promote Radiofrequency Ablation Induced Ferroptosis and Intratumoral Immune Rewiring in Hepatocellular Carcinoma

Advanced Science, EarlyView.
Targeted FABP5 co‐delivery nanoparticles amplify RFA‐induced ferroptosis and intratumoral immune rewiring via STING/TBK1 pathway activation in HCC. The pH‐responsive lipid nanoshell was integrated with cyclic RGD peptide (cRGD) and red blood cell membrane (RBCM), and encapsulated with superparamagnetic iron oxide (SPIO) and sgFABP5 to construct FS@RBCM/
Bufu Tang, Xiaojie Zhang, Yiting Sun, Jinhua Luo, Qiaoyou Weng, Cong Zhang, Zilin Wang, Shiji Fang, Yangrui Xiao, Liyun Zheng, Jianfei Tu, Rongfang Qiu, Yang Yang, Zhongwei Zhao, Weiqian Chen, Minjiang Chen, Jiansong Ji   +16 more
wiley   +1 more source

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? [PDF]

, 1999
Andreas du Bois, J.P. Neijt, J.T. Thigpen   +2 more
openalex   +1 more source

Alternative Models for Anticancer Drug Discovery From Natural Products Using Binary Tumor‐Microenvironment‐on‐a‐Chip

Advanced Science, EarlyView.
This study presents a binary tumor‐microenvironment‐on‐a‐chip (T‐MOC) system incorporating multicellular tumor spheroids (MCTs) as an alternative preclinical platform to evaluate the efficacy of anticancer natural products. The T‐MOC model reproduces in vivo drug delivery barriers and physiological conditions, enabling morphological analysis to predict
Youngwon Kim, Si Hyeon Chae, Dahae Lee, Bum Soo Lee, Jiseok Lim, Hyo‐Il Jung, Ki Hyun Kim, Bongseop Kwak   +7 more
wiley   +1 more source

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma [PDF]

, 1997
Andrea Messori, Michele Cecchi, Paola Becagli, Sabrina Trippoli   +3 more
openalex   +1 more source

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

New England Journal of Medicine, 2007
K. Miller, Molin Wang, J. Gralow, M. Dickler, M. Cobleigh, E. Perez, T. Shenkier, D. Cella, N. Davidson   +8 more
semanticscholar   +1 more source

Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation

Advanced Science, EarlyView.
A peptide that replicates the amino acid sequence in Insig1/2 loop 1 inhibits the IGF1‐induced interaction between PCK1 and Insig1/2, PCK1‐mediated phosphorylation of Insig1/2, and SREBP activity‐dependent lipid synthesis. Administration of the LNP‐Insig1/2 loop 1 peptide effectively attenuates tumor growth and sensitizes tumors to the antitumor effect
Shudi Luo, Huang Yang, Xiaoming Jiang, Zheng Wang, Xuxiao He, Ying Meng, Shan Li, Min Li, Daqian Xu, Zhengwei Mao, Zhimin Lu   +10 more
wiley   +1 more source

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro­pathy: a cross-sectional cohort study

Acta Oncologica
Background and purpose: There remains limited evidence regarding the relative neurotoxic potential of nab-paclitaxel long-term. This cross-sectional matched cohort study aimed to compare the severity and natural history of chemotherapy-induced peripheral
Terry Trinh, Kimberley Au, Arun V. Krishnan, Hannah C. Timmins, Tiffany Li, Peter Grimison, David Goldstein, Susanna B. Park   +7 more
doaj   +1 more source

TOXICITY STUDIES OF PACLITAXEL (III) : Six-month intermittent intravenous toxicity in rats

, 1994
T. Kadota, Hiroshi Kondoh, H Chikazawa, Kohji KUROYANAGI, Norimichi Hattori, K Ishikawa, Shigeo Kawano, K Sakakura, S Koizumi, E Hiraiwa   +9 more
openalex   +2 more sources